Cargando…

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma

Iguratimod is a new synthetic disease-modifying antirheumatic drug intended to treat patients with rheumatoid arthritis. A new method using recombinant human CYP450s yeast cells containing c-DNA expressed P450s was applied to identify the metabolic pathways of iguratimod and to prepare its metabolit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jun-ping, Zhu, Zhen-han, Wu, Yue-zhang, Qian, Wen, Li, Zhi-yu, Nishikawa, Miyu, Sakaki, Toshiyuki, Yang, Chang-qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706704/ https://www.ncbi.nlm.nih.gov/pubmed/31531047 http://dx.doi.org/10.22037/ijpr.2019.1100641

Ejemplares similares

Iguratimod efficacy in palindromic rheumatism treatment
por: Yuan, Fangfang, et al.
Publicado: (2023)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes
por: Lin, Jin, et al.
Publicado: (2019)

Iguratimod alleviates tubulo-interstitial injury in mice with lupus
por: Xue, Leixi, et al.
Publicado: (2022)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases
por: Lu, Wentian, et al.
Publicado: (2022)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Ciclesonide/iguratimod: Prolonged presence of SARS-CoV-2: case report
Publicado: (2020)

Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
por: Li, Yan, et al.
Publicado: (2021)

Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022)

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
por: Yan, Qingran, et al.
Publicado: (2023)

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014)

Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise
por: Tanaka, Masao
Publicado: (2021)

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases
por: Long, Zhiyong, et al.
Publicado: (2023)

Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice
por: Wang, Shuying, et al.
Publicado: (2023)

Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4
por: Hang, Zhou, et al.
Publicado: (2022)

Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis
por: Xu, Yunzhi, et al.
Publicado: (2015)

Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature
por: Li, Xiao-li, et al.
Publicado: (2018)

Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis
por: Ye, Yan, et al.
Publicado: (2019)

Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Pu, Jincheng, et al.
Publicado: (2021)

Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
por: Zhang, Juan, et al.
Publicado: (2022)

Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
por: Zeng, Huiqiong, et al.
Publicado: (2022)

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023)

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression
por: Shen, Lichong, et al.
Publicado: (2023)

A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
por: Wang, Shuhua, et al.
Publicado: (2023)

Iguratimod prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator-activated receptor-γ
por: Wu, Ying-Xing, et al.
Publicado: (2017)

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Ouyang, Dan, et al.
Publicado: (2022)

The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
por: Inoue, Asuka, et al.
Publicado: (2020)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
por: Nozaki, Yuji
Publicado: (2021)

Efficacy and Safety of Iguratimod Supplement to the Standard Immunosuppressive Regimen in Highly Mismatched Renal Transplant Recipients: A Pilot Study
por: Tao, Jun, et al.
Publicado: (2021)

Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model
por: Sun, Yue, et al.
Publicado: (2017)

Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
por: Li, Jie, et al.
Publicado: (2019)

Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway
por: Liu, Sha, et al.
Publicado: (2021)

Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum
por: Tan, Jingya, et al.
Publicado: (2021)

Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs
por: Hu, Chao-Jun, et al.
Publicado: (2021)

Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials
por: Long, Zhiyong, et al.
Publicado: (2023)

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
por: Tokai, Nao, et al.
Publicado: (2018)

Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study
por: Mu, Rong, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome
por: Zeng, Liuting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_okbh1lrfura8f746u21sg4i9gr